3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
59
Leukemia
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Gastrointestinal Stromal Tumors
12
Leukemia, Myeloid, Chronic-Phase
11
Neoplasms
5
Blast Crisis
4
Recurrence
3
Bronchiolitis Obliterans Syndrome
3
Synovitis, Pigmented Villonodular
2
Philadelphia Chromosome
2
Neoplasm Metastasis
2
Melanoma
2
Leukemia, Myeloid, Accelerated Phase
2
Leukemia, Myeloid
2
Hematologic Diseases
2
Bone Marrow Diseases
2
Sarcoma
1
Piebaldism
1
Peritoneal Neoplasms
1
Ovarian Neoplasms
1
Neurofibromatoses
1
Neurofibroma, Plexiform
1
Neurofibroma
1
Neoplastic Processes
1
Myeloproliferative Disorders
1
Mucosal Lentiginous Melanoma
1
Mastocytosis, Systemic
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Non-Hodgkin
1
Interventions
Cyclophosphamide
32
Tacrolimus
29
fludarabine
27
Mycophenolic Acid
23
fludarabine phosphate
22
Busulfan
19
Whole-Body Irradiation
18
Melphalan
16
Methotrexate
15
Antilymphocyte Serum
14
Rituximab
12
Bortezomib
11
Stem Cell Transplantation
10
Cyclosporine
10
thymoglobulin
9
Sirolimus
9
Granulocyte Colony-Stimulating Factor
9
Peripheral Blood Stem Cell Transplantation
8
Thiotepa
7
Interviews as Topic
7
Filgrastim
7
Dexamethasone
7
Clofarabine
7
Blood Specimen Collection
6
Alemtuzumab
6
merphos
5
Voriconazole
5
Standard of Care
5
Nivolumab
5
Lenalidomide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Hematologic Neoplasms
×
nilotinib
×
Clear all
NCT00471497
2020-11-18
ENESTnd
Novartis
Phase 3
Completed
846 enrolled
33 charts